Navigation Acuity

November 2018 Vol 9, NO 11
Lianna Willhite, RN, BSN, ONN-CG, CBCN
Hendricks Regional Health, Danville, IN

Background: Oncology navigation is a patient-focused, time-intensive process. Individual patient encounters occur multiple times over an extended period. A primary objective for nurse navigators is to identify and address patient barriers, then customize care delivered to minimize barriers and achieve optimal healthcare outcomes. Mitigating solutions to barriers is challenging and often requires multiple, time-intensive steps. Caseload volumes for nurse navigators are increasing as programs experience recognition and growth. A standardized method to determine navigator caseloads is merited and needs to be acuity-based rather than number-based for management efficacy and practice success.

Objective: To establish a baseline acuity score for oncology patients by utilizing distress scores and barrier numbers, then compare with the total time spent navigating the patient for correlation patterns.

Methods: Retrospectively, navigation documentation on 112 breast cancer patients from 2015 to 2017 was audited to identify patient barriers and distress scores. These numbers were then plotted on the patient navigator acuity scale to establish an acuity level for each patient. Barriers, distress score, and established acuity levels were then compared with the total navigation time logged (per hour) per patient. Correlation was used to determine the relationship between barriers, distress score, acuity level, and the total navigation time. Regression was performed to determine if any variables were predictive of navigation time.

Results: Breast cancer cases increased annually. Overall, barrier number impacted the patient’s acuity score, and the greater the number the higher the acuity. Barriers (0.001) and acuity scores (0.006) demonstrated significant correlation to navigation time. Barriers were also found to be significant predictors (0.023) of navigation time. Average time spent navigating per barrier was 0.7 to 1.0 hour. Distress scores did not show significant correlation or prediction of navigation time. Timing of distress screenings impacted test results, and were found to be inconsistent and predominately completed toward end of treatment. Limitations in the study included utilizing a barrier assessment tool developed for a community outside the study area.

Conclusion: As navigation programs evolve, a standardized method to determine acuity for caseload management is needed to support nurse navigators and ensure ongoing navigation success. Development of barrier assessment tools along with consistent screening practices for distress are warranted. This study highlights the importance of barriers and their impact on acuity and supports the need for continued research in navigation acuity for best practice development.

Sources

Hendren S, Chin N, Fisher S, et al. Patients’ barriers to receipt of care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc. 2011;103:701-710.
Horner K, Ludman E, McCorkle R, et al. An oncology nurse navigator program designed to eliminate gaps in early cancer care. Clin J Oncol Nurs. 2013;17:43-48.
Koh C, Nelson JM, Cook PF. Evaluation of a patient navigation program. Clin J Oncol Nurs. 2011;15:41-48.
Sullivan-Moore C, Cook C. Patient Navigator Acuity Tool. National Consortium of Breast Centers. http://files.ctctcdn.com/b59f4183201/350b2d96-b1a0-44e9-a585-76207345dbbb.pdf. 2015.

Related Articles
Assessment of Side Effects (SEs) Impacting Quality of Life (QOL) in Patients (Pts) Undergoing Treatment (tx) for Advanced Breast Cancer (ABC) in Clinical Practice: A Real-World (RW) Multicountry Survey
November 2022 Vol 13, No 11
To examine how SEs impacting QOL in pts with ABC are perceived.
Intracranial Activity of Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non–Small-Cell Lung Cancer (NSCLC) Enrolled in VISION
November 2022 Vol 13, No 11
To provide analysis of the intracranial activity of tepotinib in patients with METex14 skipping NSCLC with BM from the VISION study to aid oncology nurse navigators who manage this population of patients.
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
November 2022 Vol 13, No 11
MF is a rare bone marrow cancer characterized by fibrosis, abnormal blood cell production, and dysregulated JAK/STAT signaling.1,2
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country